Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06941792 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Inclisiran Effectiveness in China: a Pragmatic Randomized Trial

Study acronym: V-INVINCIBLE
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion pushed from Jan 30, 2026 to Apr 30, 2027v6
  2. Trial status: Recruiting to Active, Not Recruiting Study sites: 20 to 19v5 Show 1 more changeShow less
    • Study sites: 20 to 19
  3. Re-verified, no change to tracked fieldsv4
  4. Study sites: 1 to 20v3
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Apr 30, 2025 to Jun 17, 2025v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 30, 2025 to Jun 17, 2025
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 31 trials at risk
Heart Disease
2,136 trials monitored
See 109 trials at risk
Coronary Artery Disease
1,538 trials monitored
See 68 trials at risk
The current study will be conducted to evaluate the real-world effectiveness of inclisiran relative to standard of care (SoC) in Chinese patients with coronary heart disease (CHD), not only with the low-density lipoprotein cholesterol (LDL-C) change in 1 year, but also the LDL-C Test on Target for 1 year. This study further aims to assess the adherence, treatment patterns and satisfaction, and safety of inclisiran among Chinese patients.
Trial Details
NCT Number NCT06941792
Lead Sponsor Novartis Pharmaceuticals
Conditions Coronary Heart Disease
Enrollment 1,590 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov